Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation

Background Atrial fibrillation (AF) is associated with increasing risk of thromboembolic or ischemic stroke. The CHA2DS2‐VASc score is a well‐established predictor of AF stroke. Patients with AF have an increased risk of stroke if they have diabetes. Use of sodium‐glucose cotransporter‐2 inhibitor (...

Full description

Bibliographic Details
Main Authors:	Sheng‐Nan Chang, Jien‐Jiun Chen, Pang‐Shuo Huang, Cho‐Kai Wu, Yi‐Chih Wang, Juey‐Jen Hwang, Chia‐Ti Tsai
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	atrial fibrillation diabetes oral hypoglycemic agent sodium‐glucose cotransporter‐2 inhibitor stroke thromboembolism
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.122.027764

Similar Items

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
by: Nikolaos Karamichalakis, et al.
Published: (2022-07-01)

Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
by: Xiaolan Ouyang, et al.
Published: (2023-05-01)

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
by: Xiaodong Peng, et al.
Published: (2020-08-01)

Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinedione on New-Onset Atrial Fibrillation Risk to Patients with Type 2 Diabetes
by: Haegeun Song, et al.
Published: (2022-09-01)

Long-term efficacy of sodium-glucose cotransporter 2 inhibitor therapy in preventing atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus patients
by: Hao-Tien Liu, et al.
Published: (2023-06-01)

Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions
by: Syona S Shetty, et al.
Published: (2022-06-01)

Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data
by: Alvaro Alonso, et al.
Published: (2024-03-01)

The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor
by: Yi-Hsin Chan, et al.
Published: (2021-04-01)

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
by: Ryo Nishinarita, et al.
Published: (2021-01-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Acute kidney injury as a risk factor for atrial fibrillation after coronary artery bypass grafting — effects of sodium-glucose cotransporter-2 inhibitors
by: L. V. Kremneva, et al.
Published: (2023-12-01)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
by: Ann Wan-Chin Ling, et al.
Published: (2020-11-01)

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
by: Jiang Li, et al.
Published: (2023-10-01)

CHA2DS2VASc score predicts risk of end stage renal disease in patients with atrial fibrillation: Long-term follow-up study
by: Pang-Shuo Huang, et al.
Published: (2023-03-01)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
by: Yu-Sheng Lin, et al.
Published: (2021-06-01)

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
by: David Tak Wai Lui, et al.
Published: (2023-02-01)

Correlation Between CHA2DS2-VASc Score and Left Atrial Size in Patients With Atrial Fibrillation: A More Than 15-Year Prospective Follow-Up Study
by: Chin-Feng Tsai, et al.
Published: (2021-06-01)

Long-term outcomes of left atrial appendage occlusion in patients with atrial fibrillation and end stage renal disease
by: Sheng-Nan Chang, et al.
Published: (2024-01-01)

Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry
by: Masahiro Esato, et al.
Published: (2022-08-01)

Long-term outcomes of percutaneous left atrial appendage closure for the prevention of stroke in patients with atrial fibrillation: Asia-Pacific experience
by: Fu-Chun Chiu, et al.
Published: (2022-08-01)

Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease
by: Kuo-Hua Lee, et al.
Published: (2021-10-01)

MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015-09-01)

Atrial fibrillation in hypertrophic cardiomyopathy – A contemporary mini-review
by: Stylianos Dragasis, et al.
Published: (2022-09-01)

Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation
by: Alexander E. Berezin, et al.
Published: (2022-02-01)

Atrial Fibrillation and Cryptogenic Thromboembolic Events
by: Benhur Davi Henz, et al.

Protective Role of IRBIT on Sodium Bicarbonate Cotransporter-n1 for Migratory Cancer Cells
by: Soyoung Hwang, et al.
Published: (2020-08-01)

Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry
by: Ying Wang, et al.
Published: (2019-11-01)

Drug Therapy in Atrial Fibrillation Management: Where Do We Stand in 2010?
by: Gholamreza Davoodi, et al.
Published: (2010-10-01)

Drug Therapy in Atrial Fibrillation Management: Where Do We Stand in 2010?
by: Mehdi Montazeri, et al.
Published: (2010-11-01)

Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
by: Jaehyun Lim, et al.
Published: (2024-02-01)

Hundred years of atrial fibrillation: Current knowledge and perspectives
by: Potpara Tatjana, et al.
Published: (2010-01-01)

Maximum time between cardiac cycles in atrial fibrillation for assessing the risk of arterial thromboembolism
by: O. A. Germanova, et al.
Published: (2022-08-01)

Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation
by: Tomas Forslund, et al.
Published: (2021-08-01)

How to level the risk of bleeding while taking anticoagulant therapy in patients with atrial fibrillation?
by: Svetlana A. Berns, et al.
Published: (2022-01-01)

Antithrombotic Therapy According to the Guidelines Issued by the Japanese Circulation Society in Patients with Nonvalvular Paroxysmal Atrial Fibrillation without Thromboembolic Risk Factors
by: Mahito Ozawa, MD, et al.
Published: (2009-01-01)

Prevalence, predictors and management of left atrial appendage thrombogenic milieu in atrial fibrillation with low thromboembolic risk
by: Yu Qiao, et al.
Published: (2023-03-01)

Optimal choice of prophylactic anticoagulant therapy for nonvalvular atrial fibrillation in the context of COVID-19 pandemic
by: A. S. Polyakov, et al.
Published: (2021-09-01)

Atrial fibrillation in acute Chagas disease acquired via oral transmission: a case report
by: Paulo Fernando Pimenta de Souza, et al.

NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
by: D. A. Itkin, et al.
Published: (2015-02-01)

Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
by: S. G. Kanorskii
Published: (2016-09-01)